Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 14/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL555701 | 0.89 | SLC6A2 (0.33) | CNR2SLC6A3SLC6A2SLC6A4CCR2 | |
| SCHEMBL556119 | 0.83 | CNR2 (0.34) | CNR2SLC6A3CCR2MC4RDRD2 | |
| SCHEMBL556468 | 0.83 | CCR2 (0.34) | CNR2SLC6A3SLC6A2SLC6A4CCR2 | |
| SCHEMBL2430891 | 0.82 | CCR2 (0.38) | CNR2SLC6A3SLC6A2SLC6A4CCR2 | |
| SCHEMBL557091 | 0.81 | CCR2 (0.33) | CNR2SLC6A3CCR2MC4RDRD2 | |
| SCHEMBL4919417 | 0.73 | SLC6A3 (0.45) | CNR2SLC6A3DRD2KMT2ACNR1 | |
| SCHEMBL4926309 | 0.73 | SLC6A3 (0.45) | CNR2SLC6A3DRD2KMT2ACNR1 | |
| SCHEMBL2425249 | 0.72 | CCR1 (0.39) | CNR2SLC6A3SLC6A2SLC6A4MC4R | |
| SCHEMBL555715 | 0.71 | REN (0.55) | CNR2KMT2A | |
| SCHEMBL556590 | 0.71 | REN (0.55) | CNR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | CNR2 2092/4885SLC6A3 1655/4885SLC6A2 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.